US Patent

US8722702 — Compounds modulating c-fms and/or c-kit activity and uses therefor

Composition of Matter · Assigned to Plexxikon Inc · Expires 2027-11-21 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that modulate c-fms and/or c-kit activity, including compositions and methods for treating diseases or conditions mediated by these proteins.

USPTO Abstract

Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US8722702
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-11-21
Drug substance claim: Yes
Drug product claim: No
Assignee: Plexxikon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.